Reuben S. Harris

24.6k citations

237 papers · 17.7k indexed · 7 hit papers · h-index 69

Molecular Biology top 0.2%
Virology top 0.05%
Epidemiology top 0.2%
Immunology top 0.5%
Infectious Diseases top 0.2%

Co-authors: Michael S. Neuberger Svend K. Petersen‐Mahrt William L. Brown Mark T. Liddament Susan M. Rosenberg Michael B. Burns Mark D. Stenglein Nuri A. Temiz
Topics: HIV Research and Treatment (102 papers)HIV/AIDS drug development and treatment (57 papers)Cytomegalovirus and herpesvirus research (49 papers)
Cited by: Virology Infectious Diseases Immunology
Journals: Nature Science Cell
Partner nations: United States United Kingdom Canada

In The Last Decade

Reuben S. Harris

232 papers receiving 17.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

DNA Deamination Mediates Innate Immunity to Retroviral Infection

2003 1.1k citations Reuben S. Harris et al. profile →
AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification

2002 717 citations Reuben S. Harris et al. profile →
APOBEC3B is an enzymatic source of mutation in breast cancer

2013 639 citations Michael B. Burns, Michael A. Carpenter et al. profile →
Evidence for APOBEC3B mutagenesis in multiple human cancers

2013 559 citations Michael B. Burns, Nuri A. Temiz et al. profile →
Retroviral restriction by APOBEC proteins

2004 507 citations Reuben S. Harris et al. profile →
APOBECs and virus restriction

2015 385 citations Reuben S. Harris et al. profile →
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors

2023 94 citations Seyed Arad Moghadasi, Emmanuel Heilmann et al. Science Advances profile →

Peers

Countries citing papers authored by Reuben S. Harris

Since Specialization

Citations

This map shows the geographic impact of Reuben S. Harris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reuben S. Harris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reuben S. Harris more than expected).

Fields of papers citing papers by Reuben S. Harris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reuben S. Harris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reuben S. Harris. The network helps show where Reuben S. Harris may publish in the future.

Co-authorship network of co-authors of Reuben S. Harris

This figure shows the co-authorship network connecting the top 25 collaborators of Reuben S. Harris. A scholar is included among the top collaborators of Reuben S. Harris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reuben S. Harris. Reuben S. Harris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Virus-induced APOBEC3 transmutagenesis in bladder cancer initiation 2025 ·Science Advances ·Grace B. Hatton,Sally James,Andrew S. Mason,(unknown),(unknown),Karen Hogg,(unknown),(unknown),Anjum Khan,Matthew Welberry Smith,Michael A. Carpenter,(unknown),Iñigo Martincorena,Andrew Macdonald,Reuben S. Harris,Gabriel J. Starrett,Jennifer Southgate,Simon C. Baker	0
2	A compact stem-loop DNA aptamer targets a uracil-binding pocket in the SARS-CoV-2 nucleocapsid RNA-binding domain 2024 ·Nucleic Acids Research ·(unknown),(unknown),(unknown),(unknown),Seyed Arad Moghadasi,Ke Shi,Daniel A. Harki,Reuben S. Harris,Hideki Aihara	6
3	Human cytomegalovirus mediates APOBEC3B relocalization early during infection through a ribonucleotide reductase-independent mechanism 2023 ·Journal of Virology ·Elisa Fanunza,Adam Z. Cheng,Ashley A. Auerbach,Bojana Stefanovska,Sofia N. Moraes,James R. Lokensgard,Matteo Biolatti,Valentina Dell’Oste,Craig J. Bierle,Wade A. Bresnahan,Reuben S. Harris	6
4	Structure-guided inhibition of the cancer DNA-mutating enzyme APOBEC3A 2023 ·Nature Communications ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Tracy K. Hale,Vyacheslav V. Filichev,Elena Harjes,Reuben S. Harris,Geoffrey B. Jameson	15
5	Rapid resistance profiling of SARS-CoV-2 protease inhibitors 2023 ·PubMed ·Seyed Arad Moghadasi,(unknown),Daniel A. Harki,Reuben S. Harris	25
6	SARS-CoV-2 3CL ^pro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376 2022 ·Science Translational Medicine ·Emmanuel Heilmann,Francesco Costacurta,Seyed Arad Moghadasi,Chengjin Ye,Matteo Pavan,Davide Bassani,André Volland,(unknown),Alexander K. H. Weiss,David Bante,Reuben S. Harris,Stefano Moro,Bernhard Rupp,Luis Martínez‐Sobrido,Dorotheé von Laer	69
7	The current toolbox for APOBEC drug discovery 2022 ·Trends in Pharmacological Sciences ·(unknown),(unknown),Michael A. Carpenter,Reuben S. Harris,Daniel A. Harki	16
8	The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer 2020 ·Clinical Cancer Research ·Artur A. Serebrenik,Prokopios P. Argyris,Matthew C. Jarvis,William L. Brown,Martina Bazzaro,Rachel I. Vogel,Britt Erickson,Sun Hee Lee,Krista M. Goergen,Matthew J. Maurer,Ethan P. Heinzen,Ann L. Oberg,Yajue Huang,Xiaonan Hou,S. John Weroha,Scott H. Kaufmann,Reuben S. Harris	48
9	Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment 2019 ·Cancer Immunology Research ·Laura Evgin,Amanda L. Huff,Timothy Kottke,Jill Thompson,Amy M. Molan,Christopher B. Driscoll,Matthew Schuelke,Kevin G. Shim,Phonphimon Wongthida,Elizabeth J. Ilett,(unknown),Reuben S. Harris,Matt Coffey,José S. Pulido,Hardev Pandha,Peter J. Selby,Kevin J. Harrington,Alan Melcher,Richard G. Vile	13
10	Polyomavirus T Antigen Induces APOBEC3B Expression Using an LXCXE-Dependent and TP53-Independent Mechanism 2019 ·mBio ·Gabriel J. Starrett,Artur A. Serebrenik,(unknown),Jennifer L. McCann,Brandy Verhalen,Matthew C. Jarvis,Teneale A. Stewart,Emily K. Law,(unknown),Mengxi Jiang,John W.M. Martens,Ellen Cahir-McFarland,Paul N. Span,Reuben S. Harris	32
11	Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma 2018 ·Clinical Cancer Research ·Ju Youn Lee,Michail Schizas,Felipe C. Geyer,Pier Selenica,Salvatore Piscuoglio,Rita A. Sakr,Charlotte K.Y. Ng,(unknown),Russell Towers,Dilip D. Giri,Victor Piana de Andrade,Anastasios D. Papanastasiou,Agnès Viale,Reuben S. Harris,David B. Solit,Britta Weigelt,Jorge S. Reis‐Filho,Tari A. King	39
12	Increasing Cas9-mediated homology-directed repair efficiency through covalent tethering of DNA repair template 2018 ·Communications Biology ·Eric J. Aird,Klaus N. Lovendahl,(unknown),Reuben S. Harris,Wendy R. Gordon	184
13	Inhibiting APOBEC3 Activity with Single-Stranded DNA Containing 2′-Deoxyzebularine Analogues 2018 ·Biochemistry ·Maksim V. Kvach,(unknown),(unknown),(unknown),Geoffrey B. Jameson,(unknown),Ramkumar Moorthy,Hideki Aihara,Reuben S. Harris,Vyacheslav V. Filichev,Daniel A. Harki,Elena Harjes	36
14	Merkel Cell Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-Associated Merkel Cell Carcinoma 2017 ·mBio ·Gabriel J. Starrett,(unknown),Paul G. Cantalupo,Joshua P. Katz,Jingwei Cheng,Keiko Akagi,Manisha Thakuria,Guilherme Rabinowits,Linda C. Wang,David E. Symer,James M. Pipas,Reuben S. Harris,James A. DeCaprio	93
15	HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation 2017 ·PLoS Pathogens ·Yusuke Nakano,Naoko Misawa,(unknown),(unknown),Shinji Nakaoka,(unknown),Eri Yamada,(unknown),Rokusuke Yoshikawa,Diako Ebrahimi,(unknown),Shingo Iwami,Reuben S. Harris,Yoshio Koyanagi,Kei Sato	30
16	Functional Upregulation of the DNA Cytosine Deaminase APOBEC3B by Polyomaviruses 2016 ·Journal of Virology ·Brandy Verhalen,Gabriel J. Starrett,Reuben S. Harris,Mengxi Jiang	74
17	APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma 2016 ·Clinical Cancer Research ·Brandon Leonard,Gabriel J. Starrett,Matthew J. Maurer,Ann L. Oberg,Mieke Van Bockstal,Jo Van Dorpe,Olivier De Wever,Jozien Helleman,Anieta M. Sieuwerts,Els M.J.J. Berns,John W.M. Martens,Brett D. Anderson,William L. Brown,Kimberly R. Kalli,Scott H. Kaufmann,Reuben S. Harris	52
18	The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer 2016 ·Science Advances ·Emily K. Law,Anieta M. Sieuwerts,Kelly LaPara,Brandon Leonard,Gabriel J. Starrett,Amy M. Molan,Nuri A. Temiz,Rachel I. Vogel,Marion E. Meijer‐van Gelder,Fred C.G.J. Sweep,Paul N. Span,John A. Foekens,John W.M. Martens,Douglas Yee,Reuben S. Harris	160
19	The PKC/NF-κB Signaling Pathway Induces APOBEC3B Expression in Multiple Human Cancers 2015 ·Cancer Research ·Brandon Leonard,Jennifer L. McCann,Gabriel J. Starrett,(unknown),Elizabeth M. Luengas,Amy M. Molan,Michael B. Burns,Rebecca M. McDougle,Peter J. Parker,William L. Brown,Reuben S. Harris	106
20	Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins 2006 ·Nucleic Acids Research ·S. Jönsson,Guylaine Haché,Mark D. Stenglein,Scott C. Fahrenkrug,Valgerður Andrésdóttir,Reuben S. Harris	62

About Reuben S. Harris

Reuben S. Harris is a scholar working on Virology, Infectious Diseases and Immunology, having authored 237 papers that have together received 17.7k indexed citations. Recurring topics across this work include HIV Research and Treatment (102 papers), HIV/AIDS drug development and treatment (57 papers) and Cytomegalovirus and herpesvirus research (49 papers). The work is most often cited by research in Virology (6.9k citations), Infectious Diseases (3.9k citations) and Immunology (4.1k citations). Reuben S. Harris has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Michael S. Neuberger, Svend K. Petersen‐Mahrt, William L. Brown, Mark T. Liddament, Susan M. Rosenberg, Michael B. Burns, Mark D. Stenglein, Nuri A. Temiz, Eric W. Refsland and Judd F. Hultquist. Their work appears in journals such as Nature, Science and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact